Goldman Sachs raises Calumet stock price target to $57 on margins
Goldman Sachs raised its price target on Calumet Specialty Products Partners (CLMT) to $57 from $45, citing strong margins and balance sheet strength. The stock has surged 182% year-to-date. CLMT reported Q2 2026 revenue of $1.44B, beating estimates, but posted a loss of $1.09 per share. S&P upgraded its credit rating to 'B-' from 'CCC+'.

